INT20461

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.48
First Reported 1990
Last Reported 2010
Negated 1
Speculated 2
Reported most in Abstract
Documents 34
Total Number 35
Disease Relevance 9.58
Pain Relevance 3.66

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (Esr1) nucleus (Esr1) enzyme binding (Esr1)
DNA binding (Esr1) protein complex (Esr1) transcription factor binding (Esr1)
Anatomy Link Frequency
erythrocytes 3
MCF-7 2
brain 1
osteoclast 1
uterine 1
Esr1 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Nerve growth factor 2 100.00 Very High Very High Very High
Pain 19 99.76 Very High Very High Very High
agonist 44 99.20 Very High Very High Very High
antagonist 53 99.12 Very High Very High Very High
Inflammation 49 98.76 Very High Very High Very High
Bioavailability 21 98.58 Very High Very High Very High
Glutamate 144 97.90 Very High Very High Very High
Central nervous system 30 97.40 Very High Very High Very High
rheumatoid arthritis 110 97.20 Very High Very High Very High
Nucleus accumbens 15 96.00 Very High Very High Very High
Disease Link Frequency Relevance Heat
Metastasis 60 99.96 Very High Very High Very High
Stress Incontinence 5 99.82 Very High Very High Very High
INFLAMMATION 51 98.76 Very High Very High Very High
Apoptosis 134 98.48 Very High Very High Very High
Adenocarcinoma 1 98.04 Very High Very High Very High
Urological Neuroanatomy 19 97.92 Very High Very High Very High
Rheumatoid Arthritis 115 97.20 Very High Very High Very High
Uterine Cancer 9 96.92 Very High Very High Very High
Breast Cancer 89 95.52 Very High Very High Very High
Immunotherapy Of Cancer 5 95.40 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Bazedoxifene bound to estrogen receptor-alpha with an IC50 of 26 nm, an affinity similar to that of raloxifene.
estrogen receptor-alpha Binding (bound) of
1) Confidence 0.48 Published 2005 Journal Endocrinology Section Abstract Doc Link 15961563 Disease Relevance 0.15 Pain Relevance 0.05
(R)-(+)-7,9-difluoro-5-[4-(2-piperidin-1-ylethoxy)phenyl]-5H-6-oxachrysen-2-ol, LSN2120310, potently binds ERalpha and ERbeta and is an antagonist in MCF-7 breast adenocarcinoma and Ishikawa uterine cancer cell lines.
ERalpha Binding (binds) of in uterine associated with adenocarcinoma, uterine cancer and antagonist
2) Confidence 0.48 Published 2006 Journal J. Med. Chem. Section Abstract Doc Link 16451049 Disease Relevance 0.19 Pain Relevance 0.17
Ovariectomized Sprague-Dawley rats were treated for 2 weeks with estradiol, a specific ligand for estrogen receptor alpha (ERalpha), 4,4',4-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol (PPT) and estrogen receptor beta (ERbeta) 2,3-bis(4-hydroxyphenyl)-propionitrile (DPN), or the selective estrogen receptor modulators (SERMs) tamoxifen and raloxifene.
ERalpha Binding (ligand) of
3) Confidence 0.37 Published 2005 Journal Psychoneuroendocrinology Section Abstract Doc Link 15511599 Disease Relevance 0 Pain Relevance 0.17
In general, ESR has a complex mechanism where, on the one hand, an increase in the concentration of erythrocytes leads to a decrease in ?
ESR Binding (complex) of in erythrocytes
4) Confidence 0.37 Published 2005 Journal Biomed Eng Online Section Body Doc Link PMC1090599 Disease Relevance 0 Pain Relevance 0
In general, ESR has a complex mechanism where, on the one hand, an increase in the concentration of erythrocytes leads to a decrease in ?
ESR Binding (mechanism) of in erythrocytes
5) Confidence 0.37 Published 2005 Journal Biomed Eng Online Section Body Doc Link PMC1090599 Disease Relevance 0 Pain Relevance 0
In general, ESR has a complex mechanism where, on the one hand, an increase in the concentration of erythrocytes leads to a decrease in ?
ESR Binding (general) of in erythrocytes
6) Confidence 0.37 Published 2005 Journal Biomed Eng Online Section Body Doc Link PMC1090599 Disease Relevance 0 Pain Relevance 0
The biological properties of the molecules were screened by (1) estrogen receptor (ER) binding, (2) effect on MCF-7 cells, (3) uterotrophic effect and inhibition of estradiol induced uterotropic effect and (4) antitumor effect in DMBA induced rat mammary cancer.
estrogen receptor Binding (binding) of in MCF-7 associated with cancer
7) Confidence 0.31 Published 1990 Journal J. Steroid Biochem. Section Abstract Doc Link 2142231 Disease Relevance 0.09 Pain Relevance 0
Ovariectomized Sprague-Dawley rats were treated for 2 weeks with estradiol, a specific ligand for estrogen receptor alpha (ERalpha), 4,4',4-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol (PPT) and estrogen receptor beta (ERbeta) 2,3-bis(4-hydroxyphenyl)-propionitrile (DPN), or the selective estrogen receptor modulators (SERMs) tamoxifen and raloxifene.
estrogen receptor Binding (ligand) of
8) Confidence 0.29 Published 2005 Journal Psychoneuroendocrinology Section Abstract Doc Link 15511599 Disease Relevance 0 Pain Relevance 0.17
SERMs function by binding to the ligand binding domain of the estrogen receptor, but because of conformational differences have varying effects on coregulatory proteins associated with tissue-specific gene transcription (Miller et al 2001).
estrogen receptor Binding (binding) of
9) Confidence 0.29 Published 2007 Journal Clinical Interventions in Aging Section Body Doc Link PMC2685267 Disease Relevance 0.86 Pain Relevance 0.12
Ovariectomized Sprague-Dawley rats were treated for 2 weeks with estradiol, a specific ligand for estrogen receptor alpha (ERalpha), 4,4',4-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol (PPT) and estrogen receptor beta (ERbeta) 2,3-bis(4-hydroxyphenyl)-propionitrile (DPN), or the selective estrogen receptor modulators (SERMs) tamoxifen and raloxifene.
estrogen receptor Binding (ligand) of
10) Confidence 0.25 Published 2005 Journal Psychoneuroendocrinology Section Abstract Doc Link 15511599 Disease Relevance 0 Pain Relevance 0.20
RESULTS: Compared with participants with the ESR1 c.454-397CT or TT genotype, those with the CC genotype had a relative risk of stroke of 1.92 (95% confidence interval, 1.06 to 3.48, P=0.03) after adjustment for age, primary care practice; additional adjustment for body mass index, serum cholesterol and triglyceride levels, hypertension, diabetes, and smoking status.
ESR1 Binding (participants) of in body
11) Confidence 0.24 Published 2005 Journal Stroke Section Body Doc Link 16179580 Disease Relevance 0.09 Pain Relevance 0
LNI, SDM, ESR, and VI were independently associated with CSS after radical nephrectomy.
ESR Binding (associated) of associated with metastasis
12) Confidence 0.22 Published 2008 Journal BMC Urol Section Body Doc Link PMC2635370 Disease Relevance 1.11 Pain Relevance 0
These results suggest that estrogen regulation of the hypothalamic PPE gene expression is mediated through an estrogen-receptor complex directly interacting with the functional EREs in its promoter region; and that this estrogen effect can be modified by thyroid hormones.
estrogen-receptor Binding (interacting) of in thyroid
13) Confidence 0.21 Published 2001 Journal Brain Res. Mol. Brain Res. Section Abstract Doc Link 11457489 Disease Relevance 0 Pain Relevance 0
Reported results confirm the effectiveness of C. racemosa in menstrual distress and further emphasize the possibility that lipophilic constituents bind to an as yet not identified estrogen receptor, likely inversely involved in inflammation.
estrogen receptor Binding (bind) of associated with inflammation
14) Confidence 0.21 Published 2007 Journal J. Steroid Biochem. Mol. Biol. Section Abstract Doc Link 17689956 Disease Relevance 0.10 Pain Relevance 0.21
By means of quantitative RT-PCR we demonstrate that the upper and lower part of the bladder and the urethra express estrogen receptor of the alpha- and beta-subtype (ER alpha and beta) and nerve growth factor, which is associated with painful sensations in inflamed urinary bladders.
estrogen receptor Binding (associated) of in upper associated with pain, stress incontinence and nerve growth factor
15) Confidence 0.19 Published 2004 Journal Endocrine Section Abstract Doc Link 15034193 Disease Relevance 0.55 Pain Relevance 0.19
To determine whether ERalpha and ERbeta genes are expressed in the rat CL post-partum, we performed semiquantitative RT-PCR to specifically detect the ERalpha and ERbeta mRNA transcripts.
ERalpha Binding (detect) of
16) Confidence 0.19 Published 2005 Journal Reprod Biol Endocrinol Section Body Doc Link PMC1236958 Disease Relevance 0.09 Pain Relevance 0
Analysis of DNA-protein interactions by EMSA revealed that both ERalpha and TR (alpha1 and beta1) could bind to the EREs in the rat PPE gene promoter.
ERalpha Binding (bind) of
17) Confidence 0.16 Published 2001 Journal Brain Res. Mol. Brain Res. Section Abstract Doc Link 11457489 Disease Relevance 0.06 Pain Relevance 0
Two ERE-like elements are present between -405 and -364 of the rat PPE gene promoter, which bind ERalpha as demonstrated by EMSA.
ERalpha Binding (bind) of
18) Confidence 0.16 Published 2001 Journal Brain Res. Mol. Brain Res. Section Abstract Doc Link 11457489 Disease Relevance 0.08 Pain Relevance 0
By use of supershift assay, interactions of estrogen receptor with ERE were demonstrated in hypothalamic nuclear extracts.
estrogen receptor Binding (interactions) of
19) Confidence 0.14 Published 1995 Journal Neuroendocrinology Section Abstract Doc Link 8559277 Disease Relevance 0.08 Pain Relevance 0.04
A series of logistic regressions was performed to analyze the independent capacity of age, sex, education, RF, radiographic erosions, HAQ physical function, ESR, and SJC28 to identify people who reported that they were work-disabled due to RA (Table 4).
ESR Spec (analyze) Binding (capacity) of associated with rheumatoid arthritis
20) Confidence 0.12 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2888189 Disease Relevance 0.45 Pain Relevance 0.18

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox